ArticleHeliyon2025
Serum resistin increases in gestational diabetes but does not differ among various trimesters.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging biomarkers for gestational diabetes mellitus and related pediatric outcomes.World journal of clinical pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Resistin is inflammatory adipocytokine released from adipose and other tissue. It is thought that it is related to insulin resistance and pathogenesis of gestational diabetes mellitus (GDM). This study was aimed to determine the level of serum resistin in mothers with GDM and normal glucose tolerance (NGT) in all trimesters to see whether it differs among different trimesters as well as between GDM and NGT. Materials and methods: This cross-sectional study included 81 pregnant women with GDM and 86 NGT after challenging three samples of 75 gm oral glucose tolerance test (OGTT) following WHO-2013 criteria. Resistin was measured from serum samples obtained in fasting state during OGTT. Resistin was measured by sandwich ELISA method. Results: Resistin level [13.2(9.85, 16.0) vs. 4.66(3.53, 5.96), median (IQR); p < 0.001] was significantly higher in GDM than NGT group. This was also observed for all the trimesters [1st p < 0.001; 2nd p < 0.001; and 3rd p < 0.001 respectively] between the two groups. However, resistin showed no significant difference (p = NS for all) within each group among the three trimesters. By binary logistic regression, resistin was observed as an independent predictor for GDM (p < 0.001). On the other hand, Receiver operating characteristics (ROC) curve analysis explored resistin (AUC = 0.856; p < 0.001) as a good predictor for GDM. Conclusions: Resistin is statistically and significantly higher in GDM than that of NGT group irrespective of gestational age. It does not differ among three trimesters within any of GDM or NGT mothers. Resistin is a good predictor for GDM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.